View : 672 Download: 0

Renoprotective Effects of Mangiferin: Pharmacological Advances and Future Perspectives

Title
Renoprotective Effects of Mangiferin: Pharmacological Advances and Future Perspectives
Authors
Akter S.Moni A.Faisal G.M.Uddin M.R.Jahan N.Hannan M.A.Rahman A.Uddin M.J.
Ewha Authors
Md Jamal Uddin
SCOPUS Author ID
Md Jamal Uddinscopus
Issue Date
2022
Journal Title
International Journal of Environmental Research and Public Health
ISSN
1661-7827JCR Link
Citation
International Journal of Environmental Research and Public Health vol. 19, no. 3
Keywords
Chronic kidney diseaseInflammationKidney fibrosisMangiferinOxidative stressRenoprotective
Publisher
MDPI
Indexed
SCIE; SSCI; SCOPUS WOS scopus
Document Type
Review
Abstract
Both acute and chronic kidney diseases substantially contribute to the morbidities and mortality of patients worldwide. The existing therapeutics, which are mostly developed from syn-thetic sources, present some unexpected effects in patients, provoking researchers to explore potential novel alternatives. Natural products that have protective effects against various renal patholo-gies could be potential drug candidates for kidney diseases. Mangiferin is a natural polyphenol predominantly isolated from Mangifera indica and possesses multiple health benefits against various human ailments, including kidney disease. The main objective of this review is to update the reno-protective potentials of mangiferin with underlying molecular pharmacology and to highlight the recent development of mangiferin-based therapeutics toward kidney problems. Literature pub-lished over the past decade suggests that treatment with mangiferin attenuates renal inflammation and oxidative stress, improves interstitial fibrosis and renal dysfunction, and ameliorates structural alteration in the kidney. Therefore, mangiferin could be used as a multi-target therapeutic candidate to treat renal diseases. Although mangiferin-loaded nanoparticles have shown therapeutic promise against various human diseases, there is limited information on the targeted delivery of mangiferin in the kidney. Further research is required to gain insight into the molecular pharmacology of man-giferin targeting kidney diseases and translate the preclinical results into clinical use. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
DOI
10.3390/ijerph19031864
Appears in Collections:
연구기관 > 약학연구소 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

BROWSE